Objective: To explore the risk factors for perianal infections in patients with neutropenia and evaluate the effectiveness of different preventive measures. Methods: A r ...

Blackstone Life Sciences announced a research and development funding agreement to advance the clinical development of bleximenib, an investigational oral menin inhibitor, for acute myeloid leukemia ...

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 ...

Genetix delivers strong 2025 revenue growth resulting in the Company’s first ever profitable quarterIn 2025, >100 U.S. patients were treated and >150 U.S. patients completed their first cell ...

Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be ...

While not every patient with AML develops skin involvement, it can be one of the earliest visible signs that something systemic is occurring.

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

A mother who attributed her severe lower back pain to an old mattress was left devastated by a diagnosis of aggressive leukaemia. Gabrielle Altoft, 32, began experiencing "horrendous" discomfort in ...

First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY ...